Category Archives: Other

Yunnan Implements 2026 National Essential Medicines List From September

Kunming, Aug 24, 2026 — Yunnan’s Government Procurement and Concession Center announced that the 2026 edition of China’s National Essential Medicines List (NEML) will take effect for online trading products in the province starting Sept 1, 2026, requiring healthcare institutions and pharmaceutical suppliers to align procurement systems with the updated catalog.

Policy Snapshot

AttributeDetail
IssuerYunnan Government Procurement and Concession Center
DocumentNotice on Implementation of 2026 NEML for Online Trading Products
Effective dateSept 1, 2026
ScopeOnline trading products in Yunnan Province
Batch20268005 regularly listed products
ActionDirectory attribute labeling and system alignment

Implementation Mechanics

The center has already pushed catalog adjustment notifications directly to affected enterprises through the provincial medical insurance and procurement platform. Companies are required to log in at the official portal to review pop-up alerts; read messages remain accessible under the user message management interface. Firms without corresponding notifications are excluded from this adjustment round.

Market Impact Analysis

The Sept 1 implementation date leaves a narrow one-week window for suppliers to verify their product status and update platform registrations. The direct push-notification model—targeting only affected enterprises—streamlines compliance but risks catching smaller distributors off guard if they miss the digital alert. For manufacturers, inclusion in the 2026 NEML represents guaranteed access to Yunnan’s public hospital and primary care procurement channels, while exclusion or delisting would force reliance on non-essential drug categories with tighter reimbursement constraints.

The provincial rollout mirrors national essential medicines policy, suggesting Beijing is accelerating synchronized implementation across jurisdictions. Yunnan’s early-mover status among provincial procurement platforms may indicate the 2026 NEML is entering full national enforcement ahead of the typical staggered adoption timeline.

Forward-Looking Statement

Industry analysts expect other provincial procurement centers to issue mirror notices before year-end, triggering a wave of catalog updates across China’s public health procurement network. Pharmaceutical firms should prioritize NEML status verification on all provincial platforms where they hold active listings, as the 2026 edition introduces category adjustments that could reshape volume allocation for generic antibiotics, chronic disease medications, and traditional Chinese medicine formulations. The Yunnan template—using direct platform notifications rather than blanket public advisories—may become the standard mechanism for NEML compliance, reducing administrative overhead but increasing the importance of active platform monitoring.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27713&CatalogId=3

Shanghai Renews Centralized Drug Procurement Contracts for Third Quarter

Shanghai, Aug 24, 2026 — Shanghai’s Medical Procurement Center said it will renew centralized volume-based procurement contracts for selected drugs in the third quarter of 2026, extending agreements with winning manufacturers and their designated distributors after initial purchase volumes were fulfilled.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on the Renewal of Selected Drugs in Centralized Procurement (Q3 2026)
Effective dateSept 20, 2026
ScopeSelected drugs with expired procurement agreements and completed contracted volumes
ActionRenewal of tripartite purchase agreements among procurement center, winning manufacturers, and designated distributors

Key Provisions

  • Automatic renewal trigger — Contracts are extended for drugs that have reached the end of their initial procurement cycle and satisfied contracted purchase volumes under the volume-based procurement framework.
  • Tripartite structure — The procurement center will sign renewed purchase agreements directly with winning enterprises and their appointed distribution partners.
  • Complaint channel — Medical institutions are instructed to report any procurement issues to the procurement center during the renewal process.
  • Residual compliance — Unspecified matters will be governed by existing centralized procurement regulations and the terms of the tripartite agreements.

Market Impact Analysis

The renewal notice underscores Shanghai’s commitment to maintaining supply continuity under its volume-based procurement regime, a national pricing reform that has slashed drug costs by forcing manufacturers to bid aggressively for hospital market share. By automatically extending contracts for drugs that hit volume targets, regulators are signaling stability to winning suppliers while preventing supply disruptions that could arise from abrupt re-tendering.

For pharmaceutical companies, the renewal mechanism reduces regulatory uncertainty for products that have already secured centralized procurement slots, allowing them to plan production and distribution without navigating fresh bidding rounds. However, the notice also implicitly tightens compliance expectations—manufacturers must have fulfilled contracted volumes to qualify, penalizing those that struggled with supply or quality during the initial term.

Forward-Looking Statement

Industry observers expect the Q3 renewal wave to proceed without major disruption, given that eligible drugs have already demonstrated supply reliability. The Sept 20 effective date aligns with Shanghai’s typical procurement calendar, suggesting seamless transitions for hospital formularies. Looking ahead, the renewal template is likely to be replicated in other provincial procurement platforms as volume-based procurement contracts signed during the 2024-2025 national expansion cycle begin maturing, potentially triggering a broader wave of contract extensions across China’s public hospital network in 2027.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/24/24042.shtml

Guangdong Unifies Medical Device Listing Process for May 2025 Batch

GUANGZHOU — Guangdong Province has announced the standardization of its medical device listing process, aiming to streamline the procurement and management of medical consumables. The first batch of newly listed products for May 2025 has been published, marking a significant step toward a unified and transparent procurement system.

Policy Breakdown

  • Unified Listing Process: The Guangdong Provincial Medical Device Exchange Center has released the first batch of medical devices under the new unified listing process. This batch, designated as GDHCTYGW01-20250501, includes various medical consumables that have been reviewed and approved for inclusion in the provincial procurement system.
  • Operational Details: Companies can log in to the Guangdong Medical Device Procurement Subsystem using their CA certificates to view the listing results and manage distribution relationships. The new system ensures that all listed products are centrally managed under a unified catalog.
  • Implementation Timeline: The new listing process will be applied to all future batches, with the goal of creating a standardized and efficient procurement environment. The first batch of products will be available for contract transactions immediately, provided that distribution relationships are properly maintained.
  • Regulatory Requirements: To facilitate smooth transactions, companies are urged to complete distribution relationship maintenance as soon as possible. Detailed operational guidelines are available on the official website under “Member Services – Business Guidelines.”

Industry Impact

  • Efficiency Gains: The unified listing process is expected to reduce administrative burdens and improve the efficiency of medical device procurement for healthcare providers.
  • Market Transparency: Standardizing the listing process enhances transparency, making it easier for companies to navigate the procurement system and ensuring fair competition.
  • Quality Assurance: The centralized management of listed products ensures that only high-quality and compliant medical devices are procured, benefiting both healthcare providers and patients.

Looking Ahead
Stakeholders, including medical device manufacturers and healthcare institutions, should familiarize themselves with the new listing process and operational requirements. The long-term goal is to create a more efficient and transparent procurement environment, ultimately improving the quality and availability of medical devices in Guangdong.-China Health Reform Pulse

For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1927162319360495616